A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

NCT ID: NCT07123415

Last Updated: 2025-11-19

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 110 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-10-24
• Study Completion Date: 2028-12-31

Brief Summary

This is a Phase 1, open-label, dose-escalation study to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of APX-343A monotherapy (Part A) and in combination with pembrolizumab (Part B) in subjects with advanced solid tumors.

Conditions

Advanced Solid Cancer; Advanced Solid Tumor (Phase 1)

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Part A : APX-343A

Part A is a dose-escalation study of APX-343A monotherapy in subjects with advanced solid tumors.

Group Type: EXPERIMENTAL

APX-343A

Intervention Type: DRUG

Oral administration twice daily

Part B

Part B is a dose-escalation study of APX-343A in combination with pembrolizumab, targeting subjects with advanced solid tumors.

Group Type: EXPERIMENTAL

APX-343A

Intervention Type: DRUG

Oral administration twice daily

Pembrolizumab

Intervention Type: DRUG

intravenous \[IV\]

Interventions

APX-343A

Oral administration twice daily

Intervention Type: DRUG

Pembrolizumab

intravenous \[IV\]

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or female subjects aged ≥19 years, inclusive, at the time of informed consent.

2. Willing and able to give informed consent and to comply with the requirements of the study.

3. Histologically or cytologically confirmed advanced solid tumor.

4. Life expectancy of at least 3 months in the judgment of the investigator.

5. ECOG performance status of 0 to 1 during the screening period.

6. Measurable disease per RECIST v1.1 as assessed by the site investigator/radiology.

7. Archival tumor tissue sample or newly obtained biopsy of a tumor lesion not previously irradiated has been provided.

8. Subjects who have AEs due to previous anticancer therapies must have recovered to ≤ Grade 1 or baseline.

9. Adequate organ function as defined in the following table.

10. Subjects who are hepatitis B surface antigen positive are eligible if they have received HBV antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to the first dose of study drug.

11. Subjects with history of HCV infection are eligible if HCV viral load is undetectable at screening.

12. Male subjects must agree to use an adequate method of contraception.

13. Female subjects of childbearing potential must agree to use highly effective contraceptive methods, and to abstain from breastfeeding.

Exclusion Criteria

1. Received any prior immunotherapy.

2. Received prior systemic anticancer therapy including investigational agents.

3. Received prior radiotherapy.

4. Received a live or live-attenuated vaccine .

5. Has received an investigational agent.

6. Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy.

7. Known additional malignancy.

8. Known active CNS metastases and/or carcinomatous meningitis.

9. Active autoimmune disease.

10. History of (noninfectious) pneumonitis/interstitial lung disease.

11. Active, uncontrolled infection requiring systemic therapy.

12. Unable to swallow study drug or disease that interfere with proper absorption of study drug.

13. Significant cardiovascular disease.

14. Cerebrovascular accident.

15. History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the subject's ability to cooperate with the requirements of the study.

16. History of severe hypersensitivity to pembrolizumab and/or any of its excipients.

17. History of hypersensitivity to APX-343A and/or any of its excipients.

18. History of allogeneic tissue/solid organ transplant.

19. History of HIV infection or HIV positive at screening.

20. Subjects who have not adequately recovered from major surgery or have ongoing surgical complications.

• Minimum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Aptabio Therapeutics, Inc.

INDIV

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Seoul National University Bundang Hospital

Seongnam, , South Korea

Site Status: RECRUITING

Gangnam Severance Hospital, Yonsei University Health System

Seoul, , South Korea

Site Status: RECRUITING

Severance Hospital, Yonsei University Health System

Seoul, , South Korea

Site Status: RECRUITING

Countries

South Korea

Central Contacts

Clinical Center, Clinical Center

Role: CONTACT

cd@aptabio.com

+82-31-365-3693

Facility Contacts

Keun-Wook Lee

Role: primary

Hei-Cheul Jeung

Role: primary

Sun-Young Rha

Role: primary

Other Identifiers

APX-343A-101

Identifier Type: -

Identifier Source: org_study_id